46 research outputs found
Dendritic cells in plasmodium infection
Infection with Plasmodium parasites (malaria) contributes greatly to morbidity and mortality in affected areas. Interaction of the protozoan with the immune system has a critical role in the pathogenesis of the disease, but may also hold a key to containing parasite numbers through specific immune responses, which vaccine development aims to harness. A central player in the generation of such immune responses is the dendritic cell. However, Plasmodium parasites appear to have profound activating and suppressing effects on dendritic cell function, which may enhance immunopathology or facilitate the parasiteās survival by depressing beneficial immunity. Furthermore, immune responses to other infections and vaccines may be impaired. A greater understanding of the effects of the parasite on dendritic cells will contribute to insight and potential defeat of this infectious disease
Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo
Background: RNA interference is an evolutionary conserved immune response mechanism that
can be used as a tool to provide novel insights into gene function and structure. The ability to
efficiently deliver small interfering RNA to modulate gene expression in vivo may provide new
therapeutic approaches to currently intractable diseases.
Methods: In vitro, siRNA targeting IL-12p40 was delivered to the murine macrophage cell line
(J774A.1) encapsulated in a liposome with an IL-12 inducing agent (LPS/IFN-ĆĀ³) over a number of
time points. Controls included a variety of non-target specific siRNA reagents. Supernatants were
analyzed for cytokine production while the cells were removed for mRNA profiling.
In vivo, siRNA-targeting IL-12p40 was delivered to the murine peritoneal cavity in a therapeutic
fashion, after endotoxin (LPS) challenge. Cells from the peritoneal cavity were removed by lavage
and analyzed by flow cytometry. Levels of IL-12 present in lavage and in serum were also examined
by ELISA.
Results: In this report, we show that IL-12p40 siRNA can specifically silence macrophage
expression of IL-12p40 mRNA and IL-12p70 protein in vitro. We extend this finding to demonstrate
that delivery of liposome encapsulated siRNA targeting IL-12p40 to the murine peritoneal cavity
can modulate an inflammatory stimulus in vivo. Furthermore, specific siRNA can be used
therapeutically after endotoxin challenge to reduce both the local and systemic inflammatory
response. Thus, the delivery of siRNA can be used to elicit specific non-permanent inhibition of
endogenous protein expression.
Conclusion: In vitro silencing of IL-12p40 using siRNA at selected doses leads to specific
knockdown of IL-12p70 protein production without inducing type I interferons. Furthermore,
siRNA targeting murine IL-12p40 can be used therapeutically to counter an inflammatory response
in vivo
Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo
Background: RNA interference is an evolutionary conserved immune response mechanism that
can be used as a tool to provide novel insights into gene function and structure. The ability to
efficiently deliver small interfering RNA to modulate gene expression in vivo may provide new
therapeutic approaches to currently intractable diseases.
Methods: In vitro, siRNA targeting IL-12p40 was delivered to the murine macrophage cell line
(J774A.1) encapsulated in a liposome with an IL-12 inducing agent (LPS/IFN-ĆĀ³) over a number of
time points. Controls included a variety of non-target specific siRNA reagents. Supernatants were
analyzed for cytokine production while the cells were removed for mRNA profiling.
In vivo, siRNA-targeting IL-12p40 was delivered to the murine peritoneal cavity in a therapeutic
fashion, after endotoxin (LPS) challenge. Cells from the peritoneal cavity were removed by lavage
and analyzed by flow cytometry. Levels of IL-12 present in lavage and in serum were also examined
by ELISA.
Results: In this report, we show that IL-12p40 siRNA can specifically silence macrophage
expression of IL-12p40 mRNA and IL-12p70 protein in vitro. We extend this finding to demonstrate
that delivery of liposome encapsulated siRNA targeting IL-12p40 to the murine peritoneal cavity
can modulate an inflammatory stimulus in vivo. Furthermore, specific siRNA can be used
therapeutically after endotoxin challenge to reduce both the local and systemic inflammatory
response. Thus, the delivery of siRNA can be used to elicit specific non-permanent inhibition of
endogenous protein expression.
Conclusion: In vitro silencing of IL-12p40 using siRNA at selected doses leads to specific
knockdown of IL-12p70 protein production without inducing type I interferons. Furthermore,
siRNA targeting murine IL-12p40 can be used therapeutically to counter an inflammatory response
in vivo
Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo
Background: RNA interference is an evolutionary conserved immune response mechanism that
can be used as a tool to provide novel insights into gene function and structure. The ability to
efficiently deliver small interfering RNA to modulate gene expression in vivo may provide new
therapeutic approaches to currently intractable diseases.
Methods: In vitro, siRNA targeting IL-12p40 was delivered to the murine macrophage cell line
(J774A.1) encapsulated in a liposome with an IL-12 inducing agent (LPS/IFN-ĆĀ³) over a number of
time points. Controls included a variety of non-target specific siRNA reagents. Supernatants were
analyzed for cytokine production while the cells were removed for mRNA profiling.
In vivo, siRNA-targeting IL-12p40 was delivered to the murine peritoneal cavity in a therapeutic
fashion, after endotoxin (LPS) challenge. Cells from the peritoneal cavity were removed by lavage
and analyzed by flow cytometry. Levels of IL-12 present in lavage and in serum were also examined
by ELISA.
Results: In this report, we show that IL-12p40 siRNA can specifically silence macrophage
expression of IL-12p40 mRNA and IL-12p70 protein in vitro. We extend this finding to demonstrate
that delivery of liposome encapsulated siRNA targeting IL-12p40 to the murine peritoneal cavity
can modulate an inflammatory stimulus in vivo. Furthermore, specific siRNA can be used
therapeutically after endotoxin challenge to reduce both the local and systemic inflammatory
response. Thus, the delivery of siRNA can be used to elicit specific non-permanent inhibition of endogenous protein expression.
Conclusion: In vitro silencing of IL-12p40 using siRNA at selected doses leads to specific knockdown of IL-12p70 protein production without inducing type I interferons. Furthermore, siRNA targeting murine IL-12p40 can be used therapeutically to counter an inflammatory response
in vivo
Screening vaccine formulations for biological activity using fresh human whole blood.
Understanding the relevant biological activity of any pharmaceutical formulation destined for human use is crucial. For vaccine-based formulations, activity must reflect the expected immune response, while for non-vaccine therapeutic agents, such as monoclonal antibodies, a lack of immune response to the formulation is desired. During early formulation development, various biochemical and biophysical characteristics can be monitored in a high-throughput screening (HTS) format. However, it remains impractical and arguably unethical to screen samples in this way for immunological functionality in animal models. Furthermore, data for immunological functionality lag formulation design by months, making it cumbersome to relate back to formulations in real-time. It is also likely that animal testing may not accurately reflect the response in humans. For a more effective formulation screen, a human whole blood (hWB) approach can be used to assess immunological functionality. The functional activity relates directly to the human immune response to a complete formulation (adjuvant/antigen) and includes adjuvant response, antigen response, adjuvant-modulated antigen response, stability, and potentially safety. The following commentary discusses the hWB approach as a valuable new tool to de-risk manufacture, formulation design, and clinical progression
Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
Background.āVaccine development in human Plasmodium falciparum malaria has been hampered by the exceptionally high levels of CD8+ T cells required for efficacy. Use of potently immunogenic human adenoviruses as vaccine vectors could overcome this problem, but these are limited by preexisting immunity to human adenoviruses
T Cell Memory to Vaccination
Most immune responses associated with vaccination are controlled by specific T cells of a CD4+ helper phenotype which mediate the generation of effector antibodies, cytotoxic T lymphocytes (CTLs), or the activation of innate immune effector cells. A rapidly growing understanding of the generation, maintenance, activity, and measurement of such T cells is leading to vaccination strategies with greater efficacy and potentially greater microbial coverage
Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo
Background: RNA interference is an evolutionary conserved immune response mechanism that
can be used as a tool to provide novel insights into gene function and structure. The ability to
efficiently deliver small interfering RNA to modulate gene expression in vivo may provide new
therapeutic approaches to currently intractable diseases.
Methods: In vitro, siRNA targeting IL-12p40 was delivered to the murine macrophage cell line
(J774A.1) encapsulated in a liposome with an IL-12 inducing agent (LPS/IFN-ĆĀ³) over a number of
time points. Controls included a variety of non-target specific siRNA reagents. Supernatants were
analyzed for cytokine production while the cells were removed for mRNA profiling.
In vivo, siRNA-targeting IL-12p40 was delivered to the murine peritoneal cavity in a therapeutic
fashion, after endotoxin (LPS) challenge. Cells from the peritoneal cavity were removed by lavage
and analyzed by flow cytometry. Levels of IL-12 present in lavage and in serum were also examined
by ELISA.
Results: In this report, we show that IL-12p40 siRNA can specifically silence macrophage
expression of IL-12p40 mRNA and IL-12p70 protein in vitro. We extend this finding to demonstrate
that delivery of liposome encapsulated siRNA targeting IL-12p40 to the murine peritoneal cavity
can modulate an inflammatory stimulus in vivo. Furthermore, specific siRNA can be used
therapeutically after endotoxin challenge to reduce both the local and systemic inflammatory
response. Thus, the delivery of siRNA can be used to elicit specific non-permanent inhibition of
endogenous protein expression.
Conclusion: In vitro silencing of IL-12p40 using siRNA at selected doses leads to specific
knockdown of IL-12p70 protein production without inducing type I interferons. Furthermore,
siRNA targeting murine IL-12p40 can be used therapeutically to counter an inflammatory response
in vivo